2. Academic Validation
  3. canSAR: update to the cancer translational research and drug discovery knowledgebase

canSAR: update to the cancer translational research and drug discovery knowledgebase

  • Nucleic Acids Res. 2023 Jan 6;51(D1):D1212-D1219. doi: 10.1093/nar/gkac1004.
Patrizio di Micco 1 2,  Albert A Antolin 3,  Costas Mitsopoulos 3,  Eloy Villasclaras-Fernandez 2,  Domenico Sanfelice 2 3,  Daniela Dolciami 2,  Pradeep Ramagiri 3,  Ioan L Mica 1 2,  Joseph E Tym 2,  Philip W Gingrich 1,  Huabin Hu 3,  Paul Workman 3,  Bissan Al-Lazikani 1
Affiliations

Affiliations

  • 1 The Department of Genomic Medicine & The Institute of Data Science in Oncology, MD Anderson Cancer Center, Houston, TX, USA.
  • 2 The Department of Data Science, The Institute of Cancer Research, London, UK.
  • 3 Centre for Cancer Drug Discovery, The Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
PMID: 36624665 DOI: 10.1093/nar/gkac1004
Abstract

canSAR (https://cansar.ai) is the largest public Cancer drug discovery and translational research knowledgebase. Now hosted in its new home at MD Anderson Cancer Center, canSAR integrates billions of experimental measurements from across molecular profiling, pharmacology, chemistry, structural and systems biology. Moreover, canSAR applies a unique suite of machine learning algorithms designed to inform drug discovery. Here, we describe the latest updates to the knowledgebase, including a focus on significant novel data. These include canSAR's ligandability assessment of AlphaFold; mapping of fragment-based screening data; and new chemical bioactivity data for novel targets. We also describe enhancements to the data and interface.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z